SEEBRI Drug Patent Profile
✉ Email this page to a colleague
When do Seebri patents expire, and when can generic versions of Seebri launch?
Seebri is a drug marketed by Novartis and is included in one NDA. There are two patents protecting this drug.
This drug has ninety-nine patent family members in thirty-two countries.
The generic ingredient in SEEBRI is glycopyrrolate. There are seventeen drug master file entries for this compound. Fifty-five suppliers are listed for this compound. Additional details are available on the glycopyrrolate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Seebri
A generic version of SEEBRI was approved as glycopyrrolate by AM REGENT on July 23rd, 1986.
Summary for SEEBRI
International Patents: | 99 |
US Patents: | 2 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 113 |
Clinical Trials: | 3 |
Patent Applications: | 3,890 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for SEEBRI |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for SEEBRI |
DailyMed Link: | SEEBRI at DailyMed |
Recent Clinical Trials for SEEBRI
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Saskatchewan | Phase 4 |
Sunovion Respiratory Development Inc. | Phase 1 |
US Patents and Regulatory Information for SEEBRI
SEEBRI is protected by two US patents.
Patents protecting SEEBRI
Dry powder composition comprising co-jet milled particles for pulmonary inhalation
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Inhaler device
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | SEEBRI | glycopyrrolate | POWDER;INHALATION | 207923-001 | Oct 29, 2015 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Novartis | SEEBRI | glycopyrrolate | POWDER;INHALATION | 207923-001 | Oct 29, 2015 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for SEEBRI
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Novartis | SEEBRI | glycopyrrolate | POWDER;INHALATION | 207923-001 | Oct 29, 2015 | ⤷ Try a Trial | ⤷ Try a Trial |
Novartis | SEEBRI | glycopyrrolate | POWDER;INHALATION | 207923-001 | Oct 29, 2015 | ⤷ Try a Trial | ⤷ Try a Trial |
Novartis | SEEBRI | glycopyrrolate | POWDER;INHALATION | 207923-001 | Oct 29, 2015 | ⤷ Try a Trial | ⤷ Try a Trial |
Novartis | SEEBRI | glycopyrrolate | POWDER;INHALATION | 207923-001 | Oct 29, 2015 | ⤷ Try a Trial | ⤷ Try a Trial |
Novartis | SEEBRI | glycopyrrolate | POWDER;INHALATION | 207923-001 | Oct 29, 2015 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for SEEBRI
See the table below for patents covering SEEBRI around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
European Patent Office | 1663155 | PREPARATIONS PHARMACEUTIQUES ET DISPOSITIFS LES DISTRIBUANT (DRY POWDER COMPOSITION COMPRISING CO-JET MILLED PARTICLES FOR PULMONARY INHALATION) | ⤷ Try a Trial |
Slovakia | 103697 | POWDER FOR USE IN DRY POWDER INHALERS, METHOD OF PRODUCING AND ITS USE | ⤷ Try a Trial |
Austria | 382335 | ⤷ Try a Trial | |
Norway | 336687 | ⤷ Try a Trial | |
Australia | 2004271779 | Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for SEEBRI
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2435024 | SPC/GB21/029 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: A COMBINATION OF FORMOTEROL, INCLUDING PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS AND SOLVATES THEREOF, GLYCOPYRROLATE, INCLUDING PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS AND SOLVATES THEREOF, AND BUDESONIDE INCLUDING PHARMACEUTICALLY ACCEPTABLE SALTS, ES; REGISTERED: UK EU/1/20/1498 (NI) 20201210; UK PLGB 17901/0352-001 20201210 |
1267866 | 2013/014 | Ireland | ⤷ Try a Trial | PRODUCT NAME: GLYCOPYRRONIUM OR A SALT THEREOF; REGISTRATION NO/DATE: EU/1/12/788/001-006 20120928 |
1267866 | 300583 | Netherlands | ⤷ Try a Trial | DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT |
2435025 | LUC00124 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: UNE COMBINAISON DE GLYCOPYRROLATE (Y COMPRIS SES SELS, ESTERS, ENANTIOMERES OU AUTRES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES) ET DE FORMOTEROL (Y COMPRIS SES SELS, ESTERS, ENANTIOMERES OU AUTRES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES); AUTHORISATION NUMBER AND DATE: EU/1/18/1339 20181220 |
1267866 | C01267866/02 | Switzerland | ⤷ Try a Trial | FORMER OWNER: SOSEI R&D LTD., GB |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |